The research company Pharmalundensis is conducting a rights issue of up to approximately SEK 20 million before costs. The offering comprises up to approximately 40 million shares at a price of SEK 0.50 per share. One existing share entitles to one subscription right, and three of these entitle to subscribe for two new shares. The record date is February 4 and the subscription period runs February 6–20. Vd Staffan Skogvall intends to subscribe for at least SEK 100,000. The company is also bringing forward the year-end report to February 6.The new share issue is being carried out to finance continued marketing, production and sales of Minievaporatorer, which in the future may give Pharmalundensis the financial resources for planned clinical studies of the company's new KOL drug.